Engineered T cells for cancer treatment

Cytotherapy. 2014 Jun;16(6):713-33. doi: 10.1016/j.jcyt.2013.10.002. Epub 2013 Nov 13.


Adoptively transferred T cells have the capacity to traffic to distant tumor sites, infiltrate fibrotic tissue and kill antigen-expressing tumor cells. Various groups have investigated different genetic engineering strategies designed to enhance tumor specificity, increase T cell potency, improve proliferation, persistence or migratory capacity and increase safety. This review focuses on recent developments in T cell engineering, discusses the clinical application of these engineered cell products and outlines future prospects for this therapeutic modality.

Keywords: CAR T cells; cancer treatment; genetic modification of T cells; immunotherapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Review

MeSH terms

  • Antigens, Neoplasm / biosynthesis
  • Cell Engineering*
  • Cell- and Tissue-Based Therapy
  • Cytotoxicity, Immunologic
  • Humans
  • Immunotherapy, Adoptive
  • Neoplasms / immunology
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Recombinant Fusion Proteins / genetics*
  • Recombinant Fusion Proteins / therapeutic use
  • T-Lymphocytes / cytology
  • T-Lymphocytes / immunology*


  • Antigens, Neoplasm
  • Recombinant Fusion Proteins